The startup develops Proteolysis Targeting Chimeras (PROTACs) to selectively degrade disease-causing proteins, targeting oncology and other severe diseases. Their technology addresses the challenge of drug resistance in cancer treatment by providing a novel mechanism for targeted protein degradation.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, particularly in oncology, are caused by specific proteins. Traditional drug development faces challenges in targeting these proteins, especially when resistance to existing treatments emerges.
Solution
This startup is developing Proteolysis Targeting Chimeras (PROTACs), a technology designed to selectively degrade disease-causing proteins. By harnessing the cell's natural protein degradation pathways, PROTACs offer a novel approach to drug development, particularly for targets that are difficult to address with conventional methods. This targeted protein degradation mechanism can overcome drug resistance, offering new treatment options for severe diseases like cancer.
Target Audience
The primary target audience includes patients with cancer and other severe diseases, as well as pharmaceutical companies seeking innovative drug development approaches.
Features
- PROTAC-based therapeutics for targeted protein degradation
- Focus on oncology and other severe diseases
- Addresses drug resistance mechanisms in cancer treatment
- Novel mechanism for selectively eliminating disease-causing proteins